Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT01987830 | Bevacizumab w / Temozolomide PET & Vascular MRI For GBM | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01813877 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | completed | N/A | 37 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03687099 | Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma(GLIOBLASTOMES) | completed | — | 20 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma(ALECSAT) | completed | Phase 2 | 62 | CytoVac A/SINDUSTRY | 1 | Apr 30, 2020 | clinicaltrials |
| NCT02431572 | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | completed | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02342379 | TH-302 in Combination With Bevacizumab for Glioblastoma | completed | Phase 2 | 35 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01165671 | Carbon Ion Radiotherapy for Primary Glioblastoma(CLEOPATRA) | completed | N/A | 100 | University Hospital HeidelbergOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02529072 | Nivolumab With DC Vaccines for Recurrent Brain Tumors(AVERT) | completed | Phase 1 | 6 | Gary Archer Ph.D.OTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01067469 | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01967810 | ANG1005 in Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 73 | Angiochem IncINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01402063 | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation | completed | Phase 2 | 63 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02378532 | The Addition of Chloroquine to Chemoradiation for Glioblastoma(CHLOROBRAIN) | completed | Phase 1 | 13 | Maastricht Radiation OncologyOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00390299 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01468324 | AZD7451 for Recurrent Gliomas | completed | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00009035 | Natural History of Patients With Brain and Spinal Cord Tumors | completed | — | 3,050 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01316809 | AZD8055 for Adults With Recurrent Gliomas | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01975701 | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 4, 2019 | clinicaltrials |
| NCT01540513 | PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 | completed | N/A | 12 | University of Wisconsin, MadisonOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02893137 | Enhancing Optune Therapy With Targeted Craniectomy | completed | Phase 1 | 15 | Aarhus University HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT01392209 | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01516905 | PET/CT Imaging of Malignant Brain Tumors With 124I-NM404 | completed | — | 19 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT03722355 | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma | completed | Phase 3 | 712 | Radiation Therapy Oncology GroupNETWORK | 0 | Nov 12, 2019 | clinicaltrials |
| NCT01756352 | FET-PET for Evaluation of Response of Recurrent GBM to Avastin | completed | Phase 2 | 13 | Marcelo F. Di Carli, MD, FACCOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01989884 | An Efficacy Study Of Ortataxel In Recurrent Glioblastoma(Ortataxel) | completed | Phase 2 | 45 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00892177 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | completed | Phase 2 | 144 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02374255 | Improving Goals of Care Discussion in Advanced Cancer Patients | completed | N/A | 265 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02017249 | Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme(ArginineGBM) | completed | Phase 1 | 1 | Inova Health Care ServicesOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma(GLYRad) | completed | Phase 1 / Phase 2 | 18 | Centre Jean PerrinOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 637 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT02202993 | TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | completed | Phase 1 | 18 | Cavion, Inc.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 10, 2020source: clinicaltrials